Oxular Limited Announces Acceptance of IND for Suprachoroidal OXU-001 for the Treatment of Diabetic Macular Edema
Oxular Limited, a clinical-stage ophthalmic company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug Application (IND) for suprachoroidal OXU-001 for the treatment of diabetic macular edema (DME). The IND enables advancement of the OXEYE Phase 2 trial, which will evaluate the safety and efficacy of OXU-001 and the potential to provide retinal specialists with a potent, long-lasting, safe, and broad-acting anti-edema and anti-inflammatory treatment for high-prevalence retinal disorders, beginning with DME.
OXU-001 is dexamethasone formulated in a novel biodegradable drug preparation known as Oxuspheres®. OXU-001 will be delivered to the posterior suprachoroidal space of the eye via Oxulumis®, Oxular’s proprietary illuminated microcatheter. This in-office treatment could lead to enhanced efficacy, favorable tolerability, and extended durability to address key unmet needs for people with DME and other retinal disorders.
In 12-month preclinical studies, OXU-001 was well-tolerated and related pharmacokinetic data confirmed that therapeutic drug levels were consistently maintained in target retinal tissues. These data suggest that a single treatment of OXU-001 may provide up to twelve-month treatment effects with an improved clinical safety profile.
“The IND clearance for OXU-001 marks a significant milestone for Oxular,” said Thomas Cavanagh, Chief Executive Officer of Oxular. “DME is the most common and sight-threatening complication of diabetic eye disease and can be debilitating for patients who are often of working age. Today’s treatment approaches have limited durability, requiring frequent anti-VEGF injections into the eye. Also, typically more than two OZURDEX® implants per year may be required. The opportunity to provide patients with a targeted, in-office treatment just once a year could be a game-changer for this prevalent disease. We look forward to advancing OXU-001 into the clinic and evaluating its therapeutic impact in 2023.”
About Oxular
Oxular is a biotechnology company developing long-lasting retinal treatments, delivered suprachoroidally, to improve patients’ vision so they can live better lives. The company has engineered sustained-release drug formulations designed to last up to one year following single dosing and delivery technology to access tissues in the posterior suprachoroidal space via routine, in-office administration. This unique combination aims to substantially improve patients’ vision by increasing therapeutic effectiveness, while reducing side-effects and minimizing the frequency of treatments. Oxular is developing a deep portfolio of product candidates that includes treatments for prevalent retinal diseases, such as diabetic macular edema and diabetic retinopathy. For more information, please visit Oxular.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005116/en/
Contact information
Monique Allaire
THRUST Strategic Communications
monique@thrustsc.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ricardo Helps City of Warsaw to Introduce its First Ever Low Emission Zone28.3.2023 01:01:00 CEST | Press release
Ricardo, a global strategic environmental and engineering consulting company, has won a contract funded by the Clean Air Fund to support the City of Warsaw in Poland to assess the impacts of different Low Emission Zone (LEZ) options so that the city authority, businesses and the public has clear evidence on the costs and benefits for adopting a preferred scheme. Polish cities face severe air quality challenges. In 2018, 36 out of 50 most polluted cities in the European Union (EU) were in Poland. The country’s capital, Warsaw, is one of the most polluted cities – with exposure to air pollution having a health-related cost to society of an estimated €4.2 billion every year. It also has one of the highest vehicle ownership rates (859 per 1,000 people) in Europe and has seen a growing influx of vehicles from outside of the city. This is driven the desire by the city to introduce an ambitious Low Emission Zone in the city by 2024, but doing so in a way that does not disproportionately impac
Everen Declares $200 Million Dividend and Welcomes New Chief Operating Officer27.3.2023 22:59:00 CEST | Press release
Everen Limited (Everen) held its March 2023 Board Meeting on Tuesday, March 21st and its Annual General Meeting (AGM) on Thursday, March 23rd. During the Board Meeting, the directors approved Everen’s 2022 financial statements, discussed the ongoing execution of the 5-year Strategic Plan, and declared a dividend in the aggregate amount of $200 million payable on or before September 29, 2023 to shareholders of record on March 21, 2023. During the AGM, the Shareholders approved technical wording corrections to the Eligibility Requirements and definition of a Nuclear Facility and amended Everen’s Bye-Laws to resolve inconsistencies and elements not required by the Bermuda Companies Act 1981. They also elected a new Board of Directors who will serve for a year ending at the March 2024 AGM. The Shareholders recognized Gail Miller (VP, Human Resources) for her 18 years of service and significant contributions to the organization and also welcomed Robert Foskey into the role of Chief Operatin
Co-Founder John Keppler Rejoins Enviva Inc. as Executive Chairman of the Board27.3.2023 22:46:00 CEST | Press release
Enviva Inc. (NYSE: EVA) (“Enviva,” “our,” “we,” or the “Company”) today announced that John Keppler is returning to the Company as Executive Chairman, effective April 1, 2023. Thomas Meth will continue to lead the Company as President and Chief Executive Officer, and the Company’s interim Chairman, Ralph Alexander, will transition to the role of Lead Independent Director of the Board. Today’s announcement is consistent with the Board of Directors’ (the “Board”) governance plan as announced in November 2022, when Mr. Keppler stepped down from his role as Chairman and CEO of Enviva to address a heart condition. With Mr. Keppler’s recovery and rehabilitation following heart surgery well underway, he is returning to the Company to support his co-founding partner and CEO, Thomas Meth. As Executive Chairman, in cooperation with Mr. Meth, Mr. Keppler is expected to help drive strategic corporate initiatives, growth, and interaction with key capital markets and financial stakeholders. “I am ve
French Blood Establishment (EFS) & Brenus Pharma Partner for the GMP Production of STC-1010, an Innovative Therapy Against Colorectal Cancer27.3.2023 18:00:00 CEST | Press release
The French Blood Establishment (EFS) and Brenus Pharma announce their strategic partnership in the bioproduction of innovative therapy drugs (ITD), highlighting French expertise. This collaboration is part of a shared vision: developing the French bioproduction sector nationally and internationally. EFS’ Cell Therapy and Engineering Unit (UTICELL), based in Saint-Ismier, France, shows recognized expertise in the cell therapy field since 2003 confirmed by a European GMP Certification issued by the ANSM in 2015 for manufacturing, control and storage sites for MTIs. UTICELL also benefits from EFS’ four other certified sites’ expertise. Brenus’s proprietary platform passed key regulatory milestones in 2022 (FDA Pre-IND, EMA Scientific-Advice) and the two synergistic entities have been collaborating effectively for several months to produce GMPs batches through a first scale-up. This public-private partnership aims for a long-term perspective and will lead in 2023 to the production of clini
ETC Group Unveils New Future-Forward Global Brand27.3.2023 17:15:00 CEST | Press release
ETC Group (“ETC”), a leading global value-added distributor for the telecom network and digital infrastructure industry, announced today its intent to rebrand to Netceed. The Group’s brands will integrate into a singular organization across the globe including USTC Corp, Walker, Comstar Supply, and Multicom in the U.S.; EuroTechnoCom in France; ETCP and iETC in Portugal; Comtec in the UK, Qatar, Oman, UAE, and Hong Kong; ILDC in Israel; DNT in the Dominican Republic; ETC Morocco Networks; ETC Germany Networks; Klonex-VCS in Poland; and Tiba Produktions & Vertriebs GmbH in Austria. The unification of the Group reflects the already well-established global reach and local expertise of the companies powered by ETC Group, now coalescing them under one brand worldwide. The transition to the unified global Netceed brand is planned sequentially over six months, starting with its brands in the U.S., France, and the UK. The new name, Netceed, paired with a bold and vibrant new brand design embod